Four insights:
1. Misonix anticipates gross proceeds to reach $30 million.
2. The company will use net proceeds for corporate purposes, including investment in sales and marketing initiatives and funding growth opportunities.
3. Misonix granted underwriters a 30-day option to purchase up to an additional 243,750 shares of its common stock on the same terms and conditions.
4. The offering is expected to close on or about Jan. 27.
More articles on devices:
Bundled payments in spine: 12 key thoughts for 2020
Should pain management physicians perform endoscopic spine surgery? 8 spine specialists discuss
Medtronic CEO Omar Ishrak becomes Intel board chairman: 4 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
